B 27PD

Drug Profile

B 27PD

Alternative Names: B27PD; Optiquel; OptiquelT

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator Ludwig-Maximilians-University
  • Developer Enzo Biochem; Ludwig-Maximilians-University; National Eye Institute
  • Class Anti-inflammatories; Eye disorder therapies; Peptides
  • Mechanism of Action HLA antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Uveitis

Most Recent Events

  • 23 Sep 2015 Phase-I/II development is ongoing for Uveitis
  • 01 Aug 2010 Phase-I/II clinical trials in Uveitis in USA (PO)
  • 21 Sep 2009 Enzo establishes CRADA with the National Eye Institute for the development of B 27PD in Uveitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top